Monashee Investment Management LLC Reduces Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Monashee Investment Management LLC lessened its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 10.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 448,164 shares of the company’s stock after selling 51,836 shares during the period. Monashee Investment Management LLC owned approximately 0.33% of Compass Therapeutics worth $650,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC raised its stake in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares during the period. Geode Capital Management LLC grew its holdings in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the last quarter. SG Americas Securities LLC raised its position in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares during the period. Catalina Capital Group LLC bought a new stake in Compass Therapeutics in the fourth quarter worth about $71,000. Finally, Bleakley Financial Group LLC boosted its position in shares of Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after buying an additional 28,589 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CMPX has been the subject of a number of research analyst reports. D. Boral Capital reissued a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $13.38.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $1.84 on Wednesday. Compass Therapeutics, Inc. has a one year low of $0.77 and a one year high of $4.08. The company has a market capitalization of $254.44 million, a price-to-earnings ratio of -4.97 and a beta of 1.40. The company’s 50-day simple moving average is $2.17 and its two-hundred day simple moving average is $2.10.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Transactions at Compass Therapeutics

In other news, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction dated Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now owns 21,000 shares of the company’s stock, valued at approximately $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Corporate insiders own 28.50% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.